Race Initiates Heart Safety Preclinical Study for Bisantrene
Filed with ASX · · 3 pages · English
28 April 2021 – Race Oncology Limited (“Race”) is pleased to announce that it has entered into a collaborative preclinical research program with The University of Newcastle to investigate the heart safety Bisantrene offers over current anthracycline therapeutics. Eminent cardiotoxicity researchers, Associate Professors Aaron Sverdlov and Doan Ngo of the University of Newcastle, will lead the proje
Earlier from Racura Oncology
- Second independent study shows Bisantrene inhibits FTO
- Race Strategic Update March 2021
- Race Initiates Extramedullary AML Preclinical Study
- Race Initiates FTO Directed Kidney Cancer Preclinical Study
- Race Initiates FTO Melanoma Preclinical Study
Later from Racura Oncology
- Race investor briefing & updated presentation
- Placement closes oversubscribed-Bonus Option Issue launched
- Prospectus
- Contract to Commence Phase 2 Extramedullary AML Trial
- Race Executes Key Contract for Israel Phase 2 AML Trial
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology